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Introduction 
Transient neonatal myasthenia gravis (TNMG) is a rare and usually self-limiting condition due 
to maternal acetylcholine receptor (AChR) antibodies in neonates born to mothers with 
myasthenia gravis (MG). However, a skeletal myopathy with consistent and recognizable 
features (termed “fetal acetylcholine receptor inactivation syndrome” or FARIS) was recently 
reported in some patients [1,2]. FARIS occurs in association with clinically manifest maternal 
MG, or asymptomatically elevated maternal AChR antibodies directed against the fetal AChR 
γ subunit. Whilst in utero antibody exposure is considered the main pathogenic mechanism, 
the timing and intensity of maternal MG treatment plays an important role in determining fetal 
and postnatal outcome [1].  
The clinical spectrum of FARIS is wide, ranging from lethal arthrogryposis multiplex 
congenita (AMC) to mild, mainly facial myopathic manifestations persisting into adulthood 
[1,3]. Whilst the symptoms of typical TNMG often respond to acetylcholine esterase 
inhibition or removal of causative antibodies, FARIS does not respond to the same treatments, 
likely reflecting antibody-mediated structural endplate alterations of antenatal onset, given that 
the γ-subunit is required for the assembly of pre-patterned AChR clusters and, ultimately, 
neuromuscular synaptogenesis [4]. 
We report a child with FARIS showing dramatic symptom improvement following therapy 
with salbutamol (albuterol), a short-acting β2-adrenergic receptor agonist previously used 
effectively in specific genetic forms of congenital myasthenic syndrome (CMS). 
Case Description 
The proband (Patient 2.2 in [1]) is the second child of a previously reported family 
affected by FARIS [1,5]. His mother was diagnosed with MG in her first pregnancy. He 
had an older sibling with lethal AMC, and a younger brother with much milder 
symptoms, probably reflecting different treatment intensities of maternal MG over 
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consecutive pregnancies. He was intubated at birth and ventilated for 3 weeks. He was 
profoundly hypotonic with a weak fatigable suck and required nasogastric tube feeding, 
followed by temporary gastrostomy for 9 months. Early examinations revealed motor 
delay and marked axial, facial and bulbar weakness. He received pyridostigmine from 
birth until his second year, with little benefit beyond 2-3 months. Despite appropriate 
developmental milestones at 20 months he had persistent facial diplegia with severe 
oromotor language difficulties, a weak voice, drooling, and substantially reduced 
stamina. 
Examination at almost 5 years demonstrated severe facial muscle weakness, with an open 
mouthed expression (Figure 1A), a high arched palate, bilateral ptosis, and limited 
upgaze. His voice was dysarthric, dysphonic and weak (sentences only understood by his 
mother). Antigravity movements in neck flexion were limited (MRC grade 3-/5) but 
power was normal in all other muscles. There was no added fatigability. He was treated 
with oral Salbutamol (Albuterol) at an initial dose of 1mg three times daily. Within 48 
hours a dramatic improvement in facial expression and definition including ptosis (Figure 
1B), quality of voice and speech (now understood by most adults), general stamina 
(significantly reduced rest periods) and drooling frequency was noted. Salbutamol was 
increased to 2mg three times daily, resulting in further improvement (Figure 1C), 
confirmed on examination at 4 years 9 months. Neck flexion was MRC3+/5. Salbutamol 
benefits were sustained and treatment tolerated well.  
Conclusion 
Fetal acetylcholine receptor inactivation syndrome (FARIS) [1,2] is a recently recognized, 
early-onset myopathy due to maternal antibodies against the fetal AChR γ subunit which is 
crucial for the normal development and functioning of the embryonic neuromuscular junction 
(NMJ), a notion also supported by the marked abnormalities seen in patients with Escobar 
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syndrome due to recessive mutations in the CHRNG gene [6] causing fetal AChR γ subunit 
disruption. Absence of myasthenic features on neurophysiological assessments [1] and lack of 
response to acetylcholine esterase inhibitors in the chronic stages suggested that FARIS 
represented an “ingrained” endplate myopathy rather than an ongoing defect of neuromuscular 
transmission [1].  
Salbutamol, a β2-adrenergic agonist commenced in our patient considering its proven efficacy 
in various neuromuscular disorders and lack of response to other treatments, resulted in 
dramatic and sustained improvement. Salbutamol is highly effective in genetic CMS due to 
mutations in several genes, most notably DOK7 and COLQ, and has been demonstrated to 
improve AChR cluster assembly and NMJ architecture in a mouse model of anti-MuSK MG 
[7].  
Taken together, our observation suggests salbutamol as an effective therapy for a potentially 
severe condition for which there is currently no treatment [1]. FARIS may provide a suitable 
model to study mechanisms of salbutamol action(s) also relevant to other neuromuscular 
conditions with disturbed NMJ architecture and/or function.  
Level of Evidence:  
This study provides Class IV evidence that salbutamol improves myasthenia-related signs in 
children with FARIS. This is a single observational study without controls.  
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Figure legend 
 
Figure 1 
Facial features pre and post commencement of salbutamol treatment: Patient with Fetal 
Acetylcholine Receptor Inactivation Syndrome (FARIS) at 4 years 10 months of age. Facial 
features (A) before, (B) 24 hours after commencement of treatment with salbutamol 1mg three 
times daily, and (C) 24 hours after increase of salbutamol treatment to 2mg three times daily.  
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Figure 1 
Patient with fetal acetylcholine receptor inactivation syndrome at 4 years 9 months of 
age. Facial features (A) before, (B) 24 hours after commencement of treatment with 
salbutamol 1mg 3 times daily, and (C) 24 hours after increase of salbutamol treatment to 
2mg 3 times daily.  
 
